Source comparison
Peptides for Concussion Recovery: Mechanism Comparison
Cerebrolysin Delivers neurotrophic factors (BDNF, NGF, CNTF) to TrkB receptors; promotes neuronal survival and synaptic plasticity Partial (via receptor-mediated endocytosis) Acute (0–72 hours post-injury) Controlled cortical impact (rat model): 30–40% reducti
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Delivers neurotrophic factors (BDNF, NGF, CNTF) to TrkB receptors; promotes neuronal survival and synaptic plasticity
- Partial (via receptor-mediated endocytosis)
- Acute (0–72 hours post-injury)
- Controlled cortical impact (rat model): 30–40% reduction in lesion volume vs saline; improved Morris water maze performance at 14 days
- Gold standard for acute neuroprotection in preclinical TBI models. Strongest evidence base among peptide interventions
- Dihexa
- Binds HGF receptors; activates c-Met signaling to stimulate synaptogenesis and dendritic spine formation
- Yes (lipophilic, 750 Da)
- Subacute to chronic (72 hours to 6 weeks post-injury)
- Radiolabeled tracer studies confirm CNS accumulation; synaptic density increased 25% in hippocampal slices after 7-day administration
- Most potent synaptogenic peptide identified to date. Effect size exceeds BDNF mimetics in dendritic growth assays
- P21
- Activates JAK/STAT pathway; increases neural progenitor proliferation in dentate gyrus (hippocampal neurogenesis)
- Yes (lipid-mediated diffusion)
- Subacute (3–14 days post-injury during neurogenic window)
- Controlled cortical impact model: spatial memory restored to 85% baseline at 28 days vs 60% vehicle control
- Targets neurogenesis specifically. Ideal for cognitive recovery phase rather than acute injury mitigation
- Thymalin
- Modulates T-cell and microglial function; shifts microglia from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype
- Limited (primarily peripheral immune modulation)
- Inflammatory resolution phase (72 hours to 2 weeks)
- Fluid percussion injury model: reduced IL-1β and TNF-α levels at 7 days; no direct effect on lesion volume
- Indirect neuroprotection via systemic immune modulation. Less targeted than direct CNS-acting peptides
- MK-677 (ibutamoren)
- Ghrelin receptor agonist; stimulates growth hormone (GH) and IGF-1 release; IGF-1 crosses BBB and activates PI3K/Akt survival pathways
- Indirect (via IGF-1 upregulation)
- Chronic recovery (weeks to months for tissue remodeling)
- Human trials show 40–60% increase in serum IGF-1; animal TBI models link elevated IGF-1 to improved motor recovery
- Not a direct neuroprotective agent. Acts upstream by increasing endogenous growth factor availability over weeks